Shareholders Approve Coeptis Therapeutics' Transformative Reverse Merger with Crypto Firm Z Squared Inc.

summarizeSummary

Coeptis Therapeutics Holdings, Inc. shareholders approved the reverse merger with cryptocurrency mining firm Z Squared Inc., alongside a spin-out of its biopharmaceutical operations and a corporate name change to Z Squared Inc.

check_boxKey Events

• Shareholder Approval of Merger

  Shareholders overwhelmingly approved the reverse merger with Z Squared Inc., a cryptocurrency mining firm, marking a significant strategic pivot for the company.

• Biopharma Spin-Out Approved

  The spin-out of Coeptis' biopharmaceutical operations (excluding GEAR Therapeutics) also received strong shareholder approval, further solidifying the company's new direction.

• Name Change to Z Squared Inc. Approved

  The corporate name change from Coeptis Therapeutics Holdings, Inc. to 'Z Squared Inc.' was approved, reflecting the company's new focus on crypto assets.

• New Equity Incentive Plan Approved

  Shareholders approved the adoption of a new equity incentive plan for the combined company, a common step following a merger.

auto_awesomeAnalysis

This 8-K confirms the definitive approval by shareholders of a transformative reverse merger, fundamentally shifting Coeptis Therapeutics' business from biopharmaceuticals to cryptocurrency mining. The overwhelming approval of the merger with Z Squared Inc., the spin-out of existing biopharma operations, and the subsequent name change signal a complete strategic pivot for the company. This follows the initial announcement of the merger on January 5, 2026, and addresses the Nasdaq non-compliance notice by holding the required annual meeting. Investors should monitor the integration of Z Squared Inc. and the execution of the new crypto mining strategy.